gene editing

Bold Predictions for Medtech in 2021
Bold Predictions for Medtech in 2021
Medical Devices and Diagnostics Industry
devices
Medtech
COVID-19
remote patient monitoring
telemedicine
home care
digital medicine
artificial intelligence
machine learning
robotic surgery
3D printing
Joe Biden
gene editing
microbiome
CAR-T
Flag link:
Takeda’s gene editing partner is snapped up for $250M cash as sector continues to heat up
Takeda’s gene editing partner is snapped up for $250M cash as sector continues to heat up
Endpoints
Takeda
gene editing
Japan
AnGes
EmendoBio
Flag link:
1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive
1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive
NPR
CRISPR
gene editing
sickle cell disease
Flag link:
Bayer powers gene-editing startup Metagenomi to $65M A round
Bayer powers gene-editing startup Metagenomi to $65M A round
Fierce Biotech
Metagenomi
Bayer
CRISPR
gene therapy
gene editing
Flag link:
Intellia, beginning treatment in CRISPR study, secures Gates Foundation backing
Intellia, beginning treatment in CRISPR study, secures Gates Foundation backing
BioPharma Dive
Intellia Therapeutics
CRISPR
gene editing
Gates Foundation
Flag link:
EdiGene raises $67M to take gene-editing therapies into humans
EdiGene raises $67M to take gene-editing therapies into humans
Fierce Biotech
EdiGene
gene editing
CAR-T
beta thalassemia
ET-01
ET-02
Flag link:
Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines
Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines
Forbes
Jennifer Doudna
gene editing
Scribe Therapeutics
ALS
Flag link:
Moderna lands $100M upfront in deals with Vertex, Chiesi
Moderna lands $100M upfront in deals with Vertex, Chiesi
Fierce Biotech
Moderna Therapeutics
cystic fibrosis
R&D
Vertex Pharmaceuticals
gene editing
Chiesi
Flag link:
Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein
Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein
Forbes
Mammoth Biosciences
gene editing
CRISPR
University of California Berkeley
Flag link:
AbbVie cuts Editas CRISPR pact it inherited from Allergan
AbbVie cuts Editas CRISPR pact it inherited from Allergan
Fierce Biotech
Editas Medicine
Allergan
AbbVie
gene editing
CRISPR
Flag link:
CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment
CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment
Fierce Biotech
Vertex Pharmaceuticals
CRISPR Therapeutics
CTX001
gene editing
sickle cell disease
beta thalassemia
Flag link:
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Xconomy
gene editing
Verve Therapeutics
heart attacks
familial hypercholesterolemia
Flag link:
Stanford team deploys CRISPR gene editing to fight COVID-19
Stanford team deploys CRISPR gene editing to fight COVID-19
Fierce Biotech
Stanford University
CRISPR
gene editing
pandemic
COVID-19
Flag link:
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments
Xconomy
ViaCyte
diabetes
gene editing
stem cells
Flag link:
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia
earnings
Flag link:
How CRISPR can help us win the fight against the pandemic
How CRISPR can help us win the fight against the pandemic
MedCity News
CRISPR
gene editing
pandemic
COVID-19
R&D
Flag link:
Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%
Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%
Motley Fool
Sangamo Therapeutics
Biogen
gene therapy
gene editing
Parkinson's Disease
Alzheimer's disease
Flag link:
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
Xconomy
LogicBio Therapeutics
gene editing
clinical trials
methylmalonic acidemia
FDA
Flag link:
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Xconomy
IPOs
Beam Therapeutics
gene editing
Flag link:
This Start-up Might Be the Next Gene Editing IPO
This Start-up Might Be the Next Gene Editing IPO
Motley Fool
gene editing
Beam Therapeutics
IPOs
CRISPR
Flag link:

Pages